OBJECTIVE: To explore the effect of initiating statins for secondary prevention after a first myocardial infarction (MI) in patients aged 80 years and older.

DESIGN: Retrospective cohort study.

SETTING: Clinical Practice Research Datalink (1999-2016).

PARTICIPANTS: Patients, aged 65 years and older, hospitalized after a first MI without a statin prescription in the year before hospitalization. The age group of 65 to 80 years was included to compare our results to current evidence.

MEASUREMENTS: The primary outcome was a composite of recurrent MI, stroke, and cardiovascular mortality; and the secondary outcome was all-cause mortality. A time-varying Cox model was used to account for statin prescription over time. We compared at least 2 years of statin prescription time with untreated and less than 2 years of prescription time. Analyses were adjusted for potential confounders. The number needed to treat (NNT) was calculated based on the adjusted hazard ratios (HRs) and corrected for deaths during the first 2 years of follow-up.

RESULTS: A total of 9020 patients were included. Among the 3900 patients aged 80 years and older, 2 years of statin prescriptions resulted in a lower risk of the composite outcome (adjusted HR = 0.81; 95% confidence interval [CI] = 0.66-0.99) and of all-cause mortality (adjusted HR = 0.84; 95% CI = 0.73-0.97). During 4.5 years of median follow-up, the NNT for prevention of the primary outcome was 59; and for mortality, the NNT was 36. Correcting for 36.2% deaths during the first 2 years increased the NNT on the primary outcome to 93 and to 61 on all-cause mortality.

CONCLUSION: Our data support statin initiation after a first MI in patients aged 80 years and older if continued for at least 2 years. Especially in patients with a low risk of 2-year mortality, statins should be considered.

Key words: geriatrics; myocardial infarction; secondary prevention; statin; time varying

In patients aged 80 years and older, statin prescription rates for secondary prevention increased from 24% in 1999 to 50% to 80% in 2015. Statin treatment is initiated for secondary prevention in 3% of this population annually, so the increase in use is not only caused by the continuation of statins initiated at a younger age. However, there is little evidence to support the initiation of statins for secondary prevention in patients older than 80 years.

Two trials of secondary prevention with statin therapy after myocardial infarction (MI) in older patients (mean age = 75 years) showed 2 to 3 years of statin treatment to prevent MI, stroke, and mortality. The trials included relatively healthy participants but few patients aged 80 years and older. In clinical practice compared to trials, patients older than 80 years are typically frail, use numerous concomitant medications, and have one or more comorbid conditions. In addition, in both trials, inclusion was delayed at least 6 months after a cardiovascular event. However, the incidence of cardiovascular event recurrence is higher in the first year after a cardiovascular event than thereafter, which limits the generalizability of the results of these randomized controlled trials (RCTs) to hospitalized patients.

Most observational studies of older populations (mean age = 74-87 years) suggest that statins have a protective effect against MI recurrence and mortality. The most recent studies found no effect of statin therapy after an MI. Moreover, in these studies, statin use was defined at a fixed moment, mostly at hospital discharge, which does not account for cumulative statin exposure thereafter. Yet, up to
of initially untreated patients are prescribed statins during follow-up, of which 64\% within the first year after the primary event, and up to 42\% of patients aged 80 years and older discontinue filling statin prescriptions within 2 years of treatment initiation.\textsuperscript{14}

The current American Heart Association guidelines on blood cholesterol management recommend statin treatment to patients older than 75 years in the same way as for younger patients, except for a frailty evaluation.\textsuperscript{15} Evidence of the benefit of statin therapy in patients aged 80 years and older is needed. We, therefore, performed a large observational cohort study involving older patients. The aim of this study was to evaluate the effect of initiating statin prescription and cumulative prescriptions after a first MI in patients aged 80 years and older on the recurrence of cardiovascular events and mortality.

METHODS

Data Source

Our study was performed using data from the Clinical Practice Research Datalink (CPRD), which covers more than 11.3 million patients from 674 general practices in the United Kingdom.\textsuperscript{16} Data from CPRD were linked to the Hospital Epilepsies Statistics (HES) and linked to the Office for National Statistics (ONS) database. The protocol for this study was approved by the Independent Scientific Advisory Committee of the CPRD under protocol number 16_177R.

Study Design and Study Population

A cohort study was performed including all patients aged 65 years and older who had been hospitalized for a first MI between January 1999 and February 2016, according to the HES, with a medical history available for at least 365 days before the first MI. Although our research question was primarily focused on patients aged 80 years and older, we included patients aged 65 years up to 80 years to compare our results to current evidence in younger patients. The index date was defined as the date of hospital discharge. Patients with a prior stroke, an indication for secondary cardiovascular risk-modifying drugs after the index date was occurring follow-up or reaching the composite end point (MI, stroke, or cardiovascular mortality), they left the CPRD practice, they died, or they reached the study end date. Information on MI or stroke was collected from the HES database, and date of death and cause were retrieved from the ONS database. CPRD data were not used to identify end points given the low specificity of MI recording.\textsuperscript{18} For the secondary outcome, patients were followed up until all-cause death, as registered in the ONS database. If patients left the CPRD practice, they were censored at that time, because information on drug prescription thereafter was not available.

Potential Confounders

Known risk factors for cardiovascular diseases were defined as potential confounders and were selected from the CPRD database as Read code diagnoses or measurements before the index date. Selected potential confounders were age, sex, body mass index (BMI), smoking status (ever or never), alcohol abuse (as defined in the CPRD database), social deprivation score (according to the index of multiple deprivation), ethnicity (white or non-white), inclusion period (1999-2003, 2004-2008, or 2009-2016; the last period is 2 years longer to account for the time lapse of 2 years before statin treatment effect in the main analysis), frailty status,\textsuperscript{19} Charlson comorbidity index (0, 1-2, 3-4, or 5 or greater),\textsuperscript{20} hypertension, atrial fibrillation, number of different drugs prescribed in the 90 days before the index date, and cardiovascular drugs and other drugs known to be associated with reduced cardiovascular risk (coded according to the British National Formulary)\textsuperscript{17} (Supplementary Table S1). Exposure to cardiovascular risk-modifying drugs after the index date was also a time-varying covariate. Exposure was defined as a prescription for a drug during a specific time period.

Statistical Analysis

Data analysis was performed on cases without missing data for BMI, smoking status, alcohol use, ethnicity, or deprivation score. In subanalyses, missing data were divided at random. Baseline characteristics were compared using $\chi^2$ test for categorical variables and the $t$-test for continuous variables. For the time-varying analyses, Cox proportional hazard analyses were used, with results given as hazard ratios (HRs) with 95\% confidence intervals (CIs) and adjusted for all potential confounders. We stratified data by age, 80 years and older and 65 years up to 80 years, after investigating interaction between age and statin prescription.

In the first time-varying analyses, we compared 2 or more years of cumulative statin prescriptions, 1 to 2 years of cumulative statin prescriptions, and less than 1 year of cumulative statin prescriptions with no statin prescription. In subanalysis, patients with less than 6 months of follow-up or reaching the primary outcome within 6 months of the index date were excluded to account for treatment decisions at the index date.

We performed a second time-varying analysis comparing data for patient-time of statin prescriptions lasting more
than 2 years with data for patient-time of statin prescriptions lasting less than 2 years, including untreated time. We chose 2 years of statin prescriptions as the cutoff point, since in most trials, the time to benefit of statin treatment is 2 years.\(^3,21,22\) Sensitivity analysis was performed after excluding patients with less than 2 years of follow-up. We calculated the number needed to treat (NNT) from the HRs.\(^23\) To account for immortal time bias during the first 2 years of follow-up in the more than 2-year statin prescription group, NNTs were adjusted for mortality during the first 2 years by dividing the NNT by the survival probability 2 years after the index date.\(^24\) The median duration of follow-up was calculated from patients with more than 2 years of follow-up. To further investigate the dose-response and patient follow-up patterns, a Kaplan-Meier curve was added for the first 5 years of follow-up comparing patient-time with statin prescriptions lasting more than 2 years with data for patient-time of statin prescriptions lasting less than 2 years, including untreated time.\(^25\) At each year plus 30 days, to account for prescription lag, the number of patients contributing to each prescription group was calculated. Furthermore, the cumulative loss of patients was categorized as reaching the primary outcome, mortality, or being lost to follow-up, including reaching the study end date.

We generated the data analysis for this article using SAS software, version 9.4, of the SAS System for Windows (Copyright © 2015; SAS Institute Inc).

RESULTS

Study Population

The data of 33 151 patients older than 65 years with a first MI were available. Of these patients, 9020 fulfilled the inclusion criteria (Supplementary Figure S1), 3900 of whom were aged 80 years and older; 2594 (67%) of these patients had been prescribed a statin within 90 days of the index date (Table 1). We included 5020 patients aged 65 to

| Table 1. Baseline Table |
|-------------------------|
| Variable                | Those Aged ≥80 y | Those Between the Ages of 65-80 y |
|                         | First 90 d Statin Prescription (n = 2594) | First 90 d Untreated (n = 1306) | First 90 d Statin Prescription (n = 4305) | First 90 d Untreated (n = 815) |
| Enrollment time period  |                     |                                 |                                 |                                 |
| 1999-2003               | 376 (14.5)          | 477 (36.5)                      | 1314 (30.5)                      | 497 (61.0)                      |
| 2004-2008               | 1006 (38.8)         | 354 (27.1)                      | 1596 (37.1)                      | 144 (17.7)                      |
| 2009-2016               | 1212 (46.7)         | 475 (36.4)                      | 1395 (32.4)                      | 174 (21.4)                      |
| Age, mean (SD), y      | 85 (4.1)            | 86.9 (4.6)                      | 72.5 (4.3)                       | 73.9 (3.8)                      |
| Men                    | 1217 (46.9)         | 515 (39.4)                      | 2714 (63.0)                      | 468 (57.4)                      |
| White                  | 2555 (98.5)         | 1297 (99.3)                     | 4223 (98.1)                      | 793 (97.3)                      |
| Index of multiple deprivation: |                 |                                 |                                 |                                 |
| First quintile (least deprived) | 578 (22.3) | 249 (19.1)                      | 956 (22.2)                       | 133 (16.3)                      |
| Second quintile        | 657 (25.3)          | 305 (23.4)                      | 1085 (25.2)                      | 193 (23.7)                      |
| Third quintile         | 571 (22.0)          | 328 (25.1)                      | 903 (21.0)                       | 161 (19.8)                      |
| Fourth quintile        | 441 (17.0)          | 239 (18.3)                      | 737 (17.1)                       | 174 (21.4)                      |
| Fifth quintile (most deprived) | 347 (13.4) | 185 (14.2)                      | 624 (14.5)                       | 154 (18.9)                      |
| Ever smoker            | 1424 (54.9)         | 637 (48.8)                      | 2636 (61.2)                      | 493 (60.5)                      |
| Body mass index, mean (SD), kg/m² | 25.8 (4.3) | 25.1 (4.6)                      | 26.7 (4.4)                       | 26.6 (5.2)                      |
| Alcohol abuse          | 42 (1.6)            | 24 (1.8)                        | 124 (2.9)                        | 27 (3.3)                        |
| Frailty index          |                     |                                 |                                 |                                 |
| Fit                    | 587 (22.6)          | 196 (15.0)                      | 2487 (57.8)                      | 345 (42.3)                      |
| Mild frailty           | 1068 (41.2)         | 456 (34.9)                      | 1409 (32.7)                      | 330 (40.5)                      |
| Moderate frailty       | 703 (27.1)          | 427 (32.7)                      | 371 (8.6)                        | 109 (13.4)                      |
| Severe frailty         | 236 (9.1)           | 227 (17.4)                      | 36 (0.9)                         | 31 (3.8)                        |
| Charlson comorbidity index |                 |                                 |                                 |                                 |
| 0                      | 945 (36.4)          | 396 (30.3)                      | 2308 (53.6)                      | 316 (38.8)                      |
| 1-2                    | 1149 (44.3)         | 588 (45.0)                      | 1635 (38.0)                      | 385 (47.2)                      |
| 3-4                    | 421 (16.2)          | 253 (19.4)                      | 310 (7.2)                        | 90 (11.0)                        |
| ≥5                     | 79 (3.1)            | 69 (5.3)                        | 52 (1.2)                         | 24 (2.9)                        |
| Hypertension           | 1480 (57.1)         | 760 (58.2)                      | 1842 (42.8)                      | 371 (45.5)                      |
| Atrial fibrillation    | 329 (12.7)          | 250 (19.1)                      | 236 (5.5)                        | 86 (10.6)                       |
| No. of drugs at baseline |                 |                                 |                                 |                                 |
| 0-1                    | 426 (16.4)          | 169 (12.9)                      | 1381 (32.1)                      | 176 (21.6)                      |
| 2-4                    | 787 (30.3)          | 324 (24.8)                      | 1554 (36.1)                      | 235 (28.8)                      |
| 5-9                    | 1031 (39.8)         | 518 (39.7)                      | 1107 (25.7)                      | 278 (34.1)                      |
| ≥10                    | 350 (13.5)          | 295 (22.6)                      | 263 (6.1)                        | 126 (15.5)                      |

Note. Characteristics of patients, according to statin prescription status in the first 90 days of the index date. Values are number (percentage), unless stated otherwise. All differences were significant, with \( P < .05 \), except for mean age and ethnicity.
80 years, of whom 4305 (86%) had been prescribed a statin within 90 days of the index date. All variables, except age distribution and ethnicity, were significantly different between patients prescribed or not prescribed a statin within 90 days of the index date (Table 1).

**Primary Outcome**

As shown in Table 2, more than 2 years of statin prescriptions compared to no statin prescription was nearly significantly associated with a reduction of the primary end point in patients aged 80 years and older (adjusted HR = 0.79; 95% CI = 0.62-1.02); and there was a significant association in patients aged 65 to 80 years (adjusted HR = 0.62; 95% CI = 0.44-0.88) (Table 3). While statin prescription for 1 to 2 years had no effect on the primary outcome compared with not treated in both age groups (adjusted HR = 0.98 [95% CI = 0.75-1.29] and adjusted HR = 0.72 [95% CI = 0.49-1.05], respectively), statin prescription for less than 1 year was significantly associated with a reduction of the primary outcome in both age groups (adjusted HR = 0.80 [95% CI = 0.67-0.95] and adjusted HR = 0.51 [95% CI = 0.41-0.65], respectively). This association disappeared after the exclusion of patients with a primary outcome within the first 6 months or with less

### Table 2. Comparison of More Than 2 Years of Statin Prescription, 1 to 2 Years of Statin Prescriptions, and Less Than 1 Year of Statin Prescriptions With No Statin Prescription

| Variable                  | Prescription Group | PY  | Events | IR/1000 | HR  | HR Adj. | Patients With >6 mo FU* |
|---------------------------|--------------------|-----|--------|---------|-----|---------|-------------------------|
| **Aged ≥80 y**            |                    |     |        |         |     |         |                         |
| Primary outcome           | Untreated          | 2540| 362    | 142     | Ref.| Ref.    |                         |
| <1 y                      | 3032               | 311 | 103    | 0.58 (0.50-0.68) | 0.80 (0.67-0.95) | 0.80 (0.64-1.00) | 1.12 (0.88-1.42) |
| 1-2 y                     | 1863               | 130 | 70     | 0.74 (0.57-0.96) | 0.98 (0.75-1.29) | 0.74 (0.57-0.96) | 1.01 (0.77-1.34) |
| ≥2 y                      | 4076               | 254 | 62     | 0.61 (0.48-0.77) | 0.79 (0.62-1.02) | 0.61 (0.48-0.77) | 0.82 (0.63-1.06) |
| All-cause mortality       | Untreated          | 2673| 626    | 234     | Ref.| Ref.    |                         |
| <1 y                      | 3175               | 437 | 138    | 0.50 (0.44-0.57) | 0.71 (0.62-0.82) | 0.62 (0.52-0.73) | 0.88 (0.73-1.05) |
| 1-2 y                     | 1978               | 239 | 121    | 0.71 (0.59-0.85) | 0.99 (0.81-1.20) | 0.71 (0.59-0.85) | 1.02 (0.84-1.24) |
| ≥2 y                      | 4439               | 516 | 116    | 0.53 (0.46-0.63) | 0.79 (0.67-0.94) | 0.53 (0.46-0.63) | 0.82 (0.69-0.98) |
| **Between the Ages of 65-80 y** |                |     |        |         |     |         |                         |
| Primary outcome           | Untreated          | 1903| 159    | 84      | Ref.| Ref.    |                         |
| <1 y                      | 5197               | 220 | 42     | 0.39 (0.31-0.49) | 0.51 (0.41-0.65) | 0.78 (0.54-1.14) | 1.02 (0.68-1.52) |
| 1-2 y                     | 4061               | 90  | 22     | 0.52 (0.35-0.75) | 0.72 (0.49-1.05) | 0.50 (0.34-0.73) | 0.80 (0.54-1.18) |
| ≥2 y                      | 16 701             | 414 | 25     | 0.41 (0.29-0.56) | 0.62 (0.44-0.88) | 0.41 (0.29-0.56) | 0.65 (0.46-0.92) |
| All-cause mortality       | Untreated          | 1975| 252    | 128     | Ref.| Ref.    |                         |
| <1 y                      | 5352               | 265 | 50     | 0.33 (0.27-0.39) | 0.53 (0.44-0.65) | 0.51 (0.40-0.65) | 0.74 (0.58-0.95) |
| 1-2 y                     | 4223               | 195 | 46     | 0.59 (0.46-0.77) | 0.97 (0.75-1.25) | 0.59 (0.46-0.77) | 0.96 (0.74-1.25) |
| ≥2 y                      | 17 893             | 800 | 45     | 0.36 (0.29-0.45) | 0.62 (0.49-0.78) | 0.35 (0.28-0.43) | 0.60 (0.47-0.76) |

Abbreviations: Adj., adjusted; FU, follow-up; HR, hazard ratio; IR, incidence ratio; PY, patient-years; Ref., reference group.
*Excluding all patients with a primary event within the first 6 months of follow-up or less than 6 months of follow-up in the Clinical Practice Research Datalink practice database.

### Table 3. Effect of More Than 2 Years of Statin Prescriptions Compared With No or Less Than 2 Years of Statin Prescriptions

| Variable                  | Prescription Group | PY  | Events | IR/1000 | HR  | HR Adj. | NNT Adj. 2 y, %a | NNT Adj. 2 y | Median FU, yb |
|---------------------------|--------------------|-----|--------|---------|-----|---------|------------------|--------------|--------------|
| **Aged ≥80 y**            |                    |     |        |         |     |         |                  |              |              |
| Primary outcome           | <2 y               | 7436| 803    | 108     | Ref.|         |                  |              | 4.5          |
| ≥2 y                      | 4076               | 254 | 62     | 0.64 (0.63-0.78) | 0.81 (0.66-0.99) | 30.9 59.0 36.2 92.5 |
| All-cause mortality       | <2 y               | 7826| 1302   | 166     | Ref.|         |                  |              | 4.8          |
| ≥2 y                      | 4439               | 516 | 116    | 0.61 (0.54-0.70) | 0.84 (0.73-0.97) | 15.7 39.1 36.2 61.3 |
| **Between Ages 65-80 y**  |                    |     |        |         |     |         |                  |              |              |
| Primary outcome           | <2 y               | 11 162| 469   | 42     | Ref.|         |                  |              | 6.7          |
| ≥2 y                      | 16 701             | 414 | 25     | 0.48 (0.3-0.60) | 0.67 (0.53-0.84) | 38.7 61.3 15.5 72.5 |
| All-cause mortality       | <2 y               | 11 550| 712   | 62     | Ref.|         |                  |              | 7.2          |
| ≥2 y                      | 17 893             | 800 | 45     | 0.40 (0.38-0.52) | 0.73 (0.62-0.85) | 16.1 36.5 15.5 43.2 |

Abbreviations: Adj., adjusted; FU, follow-up; HR, hazard ratio; IR, incidence ratio; NNT, number needed to treat; PY, patient-years; Ref., reference group.
aThe percentage of patients who died within 2 years of the index date, according to the Office for National Statistics database, and patients leaving a Clinical Practice Research Datalink practice were included.
bMedian FU based on 2-year event-free survivors.
than 6 months of follow-up (adjusted HR = 1.12 [95% CI = 0.88-1.42] and adjusted HR = 1.02 [95% CI = 0.6-1.52], respectively).

Table 3 shows the effect of more than 2 years of statin prescription duration compared to less than 2 years of statin prescription on the primary outcome (ie, the composite end point of MI, stroke, and cardiovascular mortality). Two years of statin prescriptions was significantly associated with a risk reduction of the primary end point in both age groups (≥80 and 65-80 years), but the association was less pronounced in the older age group (adjusted HR = 0.81 [95% CI = 0.66-0.99] and adjusted HR = 0.67 [95% CI = 0.53-0.84], respectively). Excluding patients with less than 2 years of follow-up did not significantly change these results (adjusted HR = 0.80 [95% CI = 0.65-0.98] in patients aged ≥80 years, and adjusted HR = 0.64 [95% CI = 0.51-0.80] in patients between the age of 65 and 80 years). As the event rate was much higher in the older age group, the NNT was similar in both age categories (59.0 and 61.3, respectively). After correction for mortality in the first 2 years, the NNT in the patients aged 80 years and older increased more than that for patients aged 65 to 80 years (NNT = 92.5 and 72.5, respectively).

Figure 1 shows the Kaplan-Meier curve for primary event-free survival in patients aged 80 years and older. Curves for the primary analysis and secondary analysis and data for loss to follow-up for patients between the ages of 65 and 80 years are available in the supplementary data (Supplementary Figures S2 and S3).

Secondary Outcomes

As described in Table 2, more than 2 years of statin prescriptions compared with no statin treatment was associated with an improved all-cause mortality in both age groups of patients (≥80 years adjusted HR = 0.79 [95% CI = 0.67-0.94]; 65-80 years adjusted HR = 0.62 [95% CI = 0.49-0.78], comparable to the effect on the primary outcome. In contrast, 1 to 2 years of statin prescriptions was not associated with an effect on all-cause mortality in either patient group (≥80 years adjusted HR = 0.99 [95% CI = 0.81-1.20]; 65-80 years adjusted HR = 0.97 [95% CI = 0.7-1.25]). Less than 1 year of statin prescriptions had a comparable beneficial association on all-cause mortality as on the primary outcome, which remained after
the exclusion of patients with less than 6 months of follow-up or patients with a primary event during the first 6 months in those aged 65 to 80 years (≥80 years adjusted HR = 0.88 [95% CI = 0.73-1.05]; 65-80 years adjusted HR = 0.74 [95% CI = 0.58-0.95]). The association of more than 2 years of statin prescriptions compared with less than 2 years of statin prescriptions (including no statin prescriptions) on all-cause mortality was comparable to the effect on the primary outcome in both age groups (≥80 years adjusted HR = 0.84 [95% CI = 0.73-0.97]; 65-80 years adjusted HR = 0.73 [95% CI = 0.60-0.85]), as shown in Table 3. HRs for individual components of the primary outcome are available in Supplementary Tables S2 and S3.

DISCUSSION

Main Findings

Statin prescription initiated after a first MI in patients aged 80 years and older is associated with a reduced risk of the primary composite end point (MI, stroke, and cardiovascular mortality) and the secondary outcome (all-cause mortality) after 2 years of prescriptions, which was also seen in patients aged 65 to 80 years, although the relative association was smaller in the older patient group. Given the higher absolute risk of cardiovascular event recurrence and all-cause mortality in patients aged 80 years and older, the NNT was comparable in the two age groups. After correction for deaths during the first 2 years of follow-up, the NNT increased more in the older patient group than in the younger patient group.

Comparison of Results With Other Studies

Our results are comparable to those of a meta-analysis of the data for patients aged 65 to 80 years from secondary prevention trials, with estimated relative risk reductions of 26% to 30% on similar composite outcomes and of 26% on all-cause mortality. However, the NNT was higher in younger patient group.

Our study also had some limitations. We accounted for competing risk during the first 2 years of follow-up, but not during hospitalization or up to 30 days after discharge. If these competing risks are taken into account, the NNT may increase further. During follow-up, competing risks exist as well and patients are censored due to all-cause mortality or loss to follow-up, mostly in the less than 2 year prescription group, which may result in underestimating the effect of statin treatment. Another limitation is unmeasured confounding. In our study, we defined statin treatment on the basis of a prescription for a statin; however, we do not know whether the patients actually took the prescribed statin, which may lead to underestimation of the actual effect of statin therapy. The decision of whether to initiate statin treatment at discharge or thereafter is not random—it is associated with relevant known and unknown prognostic factors, including healthy user bias. This may overestimate the actual effect of statin therapy.

We found a positive association of statin prescriptions, consistent with the findings of most previous observational studies. However, none of these studies accounted for unmeasured confounding variables during the first 6 months of follow-up or cumulative statin exposure, as these become visible only after the index date. These studies tended to report a greater effect of statin therapy than we found, which probably is an overestimation. One study using the data from the CPRD database reported no beneficial effect of statins on MI recurrence in patients aged 80 years and older. This might be explained by the large proportion of patients in the user group (43%) who discontinued therapy within 2 years of statin initiation and by the exclusion of patients who started statin therapy more than 2 months after the event.

Strengths and Limitations

This is the first study with a large sample to investigate the initiation and cumulative statin prescriptions for secondary prevention after a first MI in patients aged 80 years and older. Our finding of a beneficial association of statins in patients aged 65 to 80 years is comparable to that of RCTs and supports the validity of our findings in the older (≥80 years) age group. The external validity is high, as all eligible patients, even the most frail, were included in our analysis, reflecting the real-life population of older patients with a first MI. Data sources for our outcomes, the combination of ONS, HES, and CPRD databases, have shown a good validity for cardiovascular diagnoses. Furthermore, by comparing different durations of statin prescriptions, we could account for unmeasured confounding during the first 6 months of treatment. In our analysis, less than 2 years of statin prescriptions appeared not to be effective in patients older than 80 years.

Issues, pleiotropic early statin initiation effects, or other unknown differences between comparison groups.

The decision to discontinue statin treatment by either the patient or the physician is also not random and may be directed by changes in the life expectancy of the patient. This may explain the larger association found for all-cause mortality of over 2 years of statin treatment, which could result in overestimation of the effect of statin treatment. Furthermore, the HES database is for hospitalized patients,
whereas not all frail patients will be referred to a hospital in acute situations, which could lead to overestimation.

Last, we performed our analysis on complete cases only; however, missing data were not associated with the initiation of statin therapy during the first 90 days after an event or with the primary outcome.

Implications for Clinicians and Policy Makers

Our results confirm that patients need to take statins for minimally 2 years after a first MI if it is likely that the patient will take the drug for at least 2 years. As the association is seen after minimally 2 years of statin prescriptions, the oldest patients (aged >80 years) with a low 2-year mortality risk should be considered for statin treatment.

CONCLUSION

Our data support starting statins in patients aged 80 years and older after a first MI if it is likely that the patient will take the drug for at least 2 years. As the association is seen after minimally 2 years of statin prescriptions, the oldest patients (aged >80 years) with a low 2-year mortality risk should be considered for statin treatment.

AKNOWLEDGMENTS

We thank and express our gratitude for the careful reviewing of our manuscript on grammar and clarity by independent English-fluent editor Jane Sykes.

Conflict of Interest: All authors have completed the International Committee of Medical Journal Editors uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work.

Author Contributions: Contributions of the authors of this article were as follows. Geert Lefebvre was involved in the conception and design of the study, statistical analysis and interpretation of data, and drafting and critical revision of the manuscript. Patrick C. Souverein was involved in conception and design of the study, acquisition of data, critical revision of the manuscript, and supervision. Anthonius de Boer and Marcel Bouvy were involved in conception and design of the study and critical revision of the manuscript. Huiberdina Koek and Wilma Knol were involved in conception and design of the study, analysis and interpretation of data, critical revision of the manuscript, and supervision.

Sponsor’s Role: There was no sponsor involved in this research.

Transparency Declaration: The lead author (Geert Lefebvre) affirms that the article is an honest, accurate, and transparent account of the study being reported; no important aspects of the study have been omitted; and any discrepancies from the study as planned and registered have been explained.

Ethical Approval: The study was approved by the Independent Scientific Advisory Committee for Clinical Practice Research Datalink (CPRD) research (protocol No. 16_177R). No further ethical approval was required for the analysis of the data. CPRD has obtained ethical approval from a multicenter research ethics committee for all purely observational research using CPRD data.

Data Sharing Statement: Data from the Clinical Practice Research Datalink (CPRD) are available directly from CPRD. Full code lists are available from the corresponding author at g.l.lefebvre@umcutrecht.nl.

Patient and Public Involvement Statement: No patients were involved in the design or execution of the study or were asked to advise on the interpretation or writing up of results.

REFERENCES

1. Johansen ME, Green LA. Statin use in very elderly individuals, 1999-2012. JAMA Intern Med. 2015;175(10):1715. https://doi.org/10.1001/jamainternmed.2015.4302.
2. Guilford M, Ravindrarajah R, Hamada S, Jackson S, Charlton J. Inception and deprescribing of statins in people aged over 80 years: cohort study. Age Ageing. 2017;46(6):1001-1005. https://academic.oup.com/ageag/article/46/6/1001/3896022.
3. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630. https://linkinghub.elsevier.com/retrieve/pii/S014067360211600X.
4. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,336 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22. http://www.sciencedirect.com/science/article/pii/S0140673602093273.
5. Aflalo J, Duque G, Steele R, Jukema JW, de Craen AJM, Eisenberg MJ. Statins for secondary prevention in elderly patients. J Am Coll Cardiol. 2008;51(1):37-45. http://linkinghub.elsevier.com/retrieve/pii/S0735109707003180.
6. Smolins K, Wright FL, Rayner M, Goldberg MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5(4):532-540. https://doi.org/10.1161/CIRCOUTCOMES.111.964700.
7. Grünso K, Melander O, Wallentin L, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol. 2010;53(13):1362-1369. http://linkinghub.elsevier.com/retrieve/pii/S0735109710003645.
8. Macle Foody J, Rathore SS, Gulsud D, et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age - statin interaction. J Am Geriatr Soc. 2006;54(3):421-430. https://doi.org/10.1111/j.1532-5415.2005.00635.x.
9. Cooke CA, Kirkland SA, Sketris I, Cox J. The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease: a cohort study. BMC Health Serv Res. 2009;9(1):198. https://doi.org/10.1186/1472-6963-9-198.
10. Allen Marcecock CA, Mullestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002;40(10):1777-1785. http://linkinghub.elsevier.com/retrieve/pii/S0735109702024774.
11. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;89(1):67-69. http://linkinghub.elsevier.com/retrieve/pii/S0002914901021671.
12. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177. https://doi.org/10.1001/jama.297.2.177.
13. Rothschild DP, Novak E, Rich MW. Effect of statin therapy on mortality in older adults hospitalized with coronary artery disease: a propensity-adjusted analysis. J Am Geriatr Soc. 2016;64(7):1475-1479.

14. Ble A, Hughes PM, Delgado J, et al. Safety and effectiveness of statins for prevention of recurrent myocardial infarction in 12 156 typical older patients: a quasi-experimental study. J Gerontol A Biol Sci Med Sci. 2017;72(2):243-250. https://doi.org/10.1093/gerona/glw082.

15. Fellowship C, Program T, Program I. Correction to : 2018 AHA / ACC / AACPVR / AAPA / ABC / APCHP / AHA / AGS / APA / ASPC / NHLA / PCNA Guideline on the Management of Blood Cholesterol : A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. 2019;73(2):3237-41.

16. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836. https://doi.org/10.1093/ije/dyv098.

17. Joint Formulary Committee. British National Formulary. 69th ed. London, England: BMJ Group and Pharmaceutical Press; 2015 https://www.bnf.org/.

18. Bhattachar N, Charlton J, Rudisill C, Gulliford MC. Coding, recording and incidence of different forms of coronary heart disease in primary care. PloS One. 2012;7(1):e29776. https://doi.org/10.1371/journal.pone.0029776.

19. Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45(3):353-360. https://doi.org/10.1093/ageing/afw039.

20. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson index for Read/OXMIS coded databases. BMC Fam Pract. 2010;11(1):1. https://doi.org/10.1186/1471-2296-11-1.

21. Holmes HM, Min LC, Yee M, et al. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. Drugs Aging. 2013;30(9):655-666. https://doi.org/10.1007/s40266-013-0095-7.

22. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. https://doi.org/10.1056/NEJMoais0807646.

23. Stang A, Poole C, Bender R. Common problems related to the use of number needed to treat. J Clin Epidemiol. 2010;63(8):820-825. http://linkinghub.elsevier.com/retrieve/pii/S089543560900239X.

24. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010;58(4):783-787. https://doi.org/10.1111/j.1532-5415.2010.02767.x.

25. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res. 2002;11(2):68-74. https://doi.org/10.1002/mpr.124.

26. Vale N, Nordmann AJ, Schwartz GG, et al. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2014(9). http://doi.wiley.com/10.1002/14651858.CD006870.pub3 Accessed Aug 31, 2018.

27. Glebsky MJ, Hoover DR. Survivor treatment selection bias in observational studies: examples from the AIDS literature. Ann Intern Med. 1996;124(11):999. https://doi.org/10.7326/0003-4819-124-11-199606100-00008.

28. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338(21):1516-1520. https://doi.org/10.1056/NEJM199805213382106.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article.

Supplementary Figure S1: Inclusion flowchart.

Supplementary Table S1: Time Under Percentual Prescription of Medication at Baseline and During Follow-Up for Each Prescription Group in Patients Aged 80 Years and Older and Between the Ages of 65 and 80 Years

Supplementary Table S2: Comparison of Effect of More Than 2 Years of Statin Treatment, 1 to 2 Years of Statin Treatment, and Less Than 1 Year of Statin With No Treatment on the Individual Components of the Primary Outcome

Supplementary Table S3: Effect of More Than 2 Years of Statin Treatment Compared With No or Less Than 2 Years of Statin Prescriptions on the Individual Components of the Primary Outcome

Supplementary Figure S2: Time-varying Kaplan-Meier curve for the primary outcome in patients between the ages of 65 and 80 years: comparison of more than 2 years of statin prescriptions with no or less than 2 years of statin prescriptions.

Supplementary Figure S3: Time-varying Kaplan-Meier curve for the primary outcome in patients aged 80 years and older and between the ages of 65 and 80 years: comparison of more than 2 years of statin prescriptions, 1 to 2 years of statin prescriptions, and less than 1 year of statin prescriptions with no statin prescriptions.